Influx Healthtech Ltd (INFLUX) — shareholding pattern, promoter holding, financials and share price
About Influx Healthtech Ltd (INFLUX)
Influx Healthtech Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as INFLUX and on the BSE under scrip code 93847. Its ISIN is INE0MYZ01012.
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing. [1]
Influx Healthtech Limited is a contract development and manufacturing organization (CDMO) specializing in nutraceuticals, cosmetics, pet care, and homecare products.
The company reported a noteworthy 39% increase in revenue for H1 FY26, reaching INR 66.8 crores, driven mainly by its nutraceutical segment. Meanwhile, EBITDA rose by 61% during the same period.
Listed peers in Pharmaceuticals: Anlon Healthcare Ltd, Anuh Pharma Ltd, Amanta Healthcare Ltd, Kilitch Drugs (India) Ltd, Zim Laboratories Ltd, Haleos Labs Limited.
Valuation & Returns
10 Jul 2026At ₹289 a share on 10 Jul 2026, Influx Healthtech Ltd (INFLUX) was valued at a price-to-earnings ratio of 32.58x against an industry P/E of 36.41x and a price-to-book of 6.64x on a book value of ₹43.52 per share. Solomo computes return on equity of 20.38% and return on capital employed of 27.21% from filed results.
- P/E
- 32.58x
- Industry P/E
- 36.41x
- P/B
- 6.64x
- EPS (TTM)
- ₹7.36
- Book value / share
- ₹43.52
- ROE
- 20.38%
- ROCE
- 27.21%
- Debt / equity
- 0x
- Dividend yield
- 0%
- 52-week range
- ₹141 – ₹315
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Influx Healthtech Ltd (INFLUX) reported revenue of ₹147 crore, net profit of ₹21 crore and earnings per share of ₹8.87. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹80 crore and net profit ₹11 crore (standalone).
| Metric | Mar 2026 |
|---|---|
| Revenue (₹ cr) | 147 |
| Net profit (₹ cr) | 21 |
| EPS (₹) | 8.87 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 14.65% | 4.88% |
| Profit growth | 43.70% | 20.13% |
| Stock price CAGR | - | 80% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 73.53% of Influx Healthtech Ltd (INFLUX). Market capitalisation was ₹669 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Mar 2026: KULBHUSHAN PARASHAR 1.87%, CCV EMERGING OPPORTUNITIES FUND-I 1.85%, AARTH AIF GROWTH FUND 1.4%, FINAVENUE CAPITAL TRUST - FINAVENUE GROWTH FUND 1.35%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 73.53% | - | - | - | - |
| Sep 2025 | 73.53% | - | - | - | - |